Search clinical trials for: Insulin Glargin (U100)

Total 5059 results

University Hospital Tuebingen

Withdrawn

Empagliflozin Effect on Glucose Toxicity

Type2 Diabetes Mellitus

Germany
Sanofi

Completed

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure (EAGLE)

Diabetes Mellitus, Type 2

Brazil, United States, Finland, Spain, Austria, Canada, Czech Republic, France, Greece, Ireland, Israel, Mexico, Netherlands, Russian Federation, Slovakia, Sweden, Turkey
Eli Lilly and Company

Completed

Lispro Mix 25 vs. Glargine in Type 2 Diabetics (IOOL)

Diabetes Mellitus Type 2

Mexico
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Diabetes Mellitus, Type 2 | Diabetes

United Arab Emirates, Malaysia, India, South Africa, Algeria, Lebanon
Eli Lilly and Company

Completed

A Study of LY3209590 in Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada
Sanofi

Completed

Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus

Diabetes Mellitus

Sweden, Finland, Netherlands, United Kingdom
Daiichi Sankyo, Inc.

Completed

Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Hoffmann-La Roche

Terminated

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Diabetes Mellitus Type 2

China, Hong Kong, Korea, Republic of, Philippines, Taiwan, Malaysia, Thailand
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

China
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Egypt
University of Alabama at Birmingham

Recruiting

Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes

Diabetes Mellitus, Type 2 | Preterm Birth | Pregnancy, High Risk | Diabetes, Gestational

United States
Sanofi
Population Health Research Institute

Completed

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) (ORIGIN)

Diabetes Mellitus, Non-Insulin-Dependent

United States, France, Brazil, Poland, Romania, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, India, Philippines, Russian Federation, Slovakia, Mexico, Argentina, Croatia, Austria, Denmark, Finland, Hungary, Lithuania, Norw... and more
Novo Nordisk A/S

Completed

Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark, Sweden, Norway
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs

Type 2 Diabetes

China
Eli Lilly and Company

Completed

A Study of LY2963016 in Healthy Participants

Healthy Volunteers

Singapore
Eli Lilly and Company

Completed

A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects

Diabetes Mellitus

Singapore
Sanofi

Completed

Glycemic Optimization Treatment Study (GOT)

Diabetes Mellitus, Type 2
Amsterdam UMC, location VUmc

Completed

Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes (LIBRA)

Obesity | Type 2 Diabetes

Netherlands
Novo Nordisk A/S

Completed

Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

China
AstraZeneca
Eli Lilly and Company

Completed

A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Sweden, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Estonia, Romania, Finland, Netherlands, Argentina, Belgium, Germany, Portugal, United Kingdom, Greece, France, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes (PreFER)

Diabetes Mellitus, Type 2 | Diabetes

Austria, Germany, Switzerland
Dance Biopharm Inc.
Profil Institut für Stoffwechselforschung GmbH

Completed

Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

Germany
AstraZeneca
Juvenile Diabetes Research Foundation

Completed

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
University of Colorado, Denver

Completed

Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes

Type 1 Diabetes Mellitus | Diabetic Ketoacidosis

United States
Eli Lilly and Company

Completed

A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
Eli Lilly and Company

Completed

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

Type 2 Diabetes

United States, Puerto Rico
Eli Lilly and Company

Completed

A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin (OPTIMIZATION)

Diabetes Mellitus, Type 2

China
Sanofi

Completed

20 Week Bridging Study in Type II DM

Diabetes Mellitus Type II
Northwestern University

Terminated

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

Insulin Resistance, Diabetes | Hyperglycemia Steroid-induced

United States
Novo Nordisk A/S

Completed

Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes (UPGRADE)

Diabetes Mellitus, Type 2 | Diabetes

Italy
Hoffmann-La Roche

Completed

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Diabetes Mellitus Type 2

Australia, Belgium, Hong Kong, United States, Germany, Portugal, Russian Federation, France, Canada, Finland, Austria, New Zealand, Spain, Poland, Thailand, Italy, Serbia, Korea, Republic of, Hungary, Mexico, Greece, Puerto Rico, Gu... and more
Novo Nordisk A/S

Completed

Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Spain, Germany, Finland, France
Sanofi

Completed

Insulin Glargine Combination Therapies in Type II Diabetics (LAPTOP)

Diabetes Mellitus, Type 2

France, Germany, Netherlands, Spain, Sweden, Switzerland, United Kingdom, Finland, Italy, Austria
CPEX Pharmaceuticals Inc.

Completed

Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus (CPEX-011)

Type 2 Diabetes

United States
Eli Lilly and Company

Completed

A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India

Type 2 Diabetes Mellitus

India
Eli Lilly and Company

Completed

A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Two Formulations of Biphasic Insulin Aspart 70

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Poland, Russian Federation, Spain, Sweden, Netherlands, Singapore, Malaysia, France, Croatia, Romania, United Kingdom, Hong Kong
Novo Nordisk A/S

Completed

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (A1chieve®)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Algeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Islamic Republic of, Jordan, Korea, Republic of, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russian Federation and more
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

United Kingdom, France, Netherlands, Belgium, Ireland
HealthPartners Institute

Terminated

Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis

DKA

United States
Profil Institut für Stoffwechselforschung GmbH
Sanofi

Completed

Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying

Diabetes Mellitus

Germany
Sanofi

Completed

Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus (Pen Preference)

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

Investigation of the Response Relationship of NN5401 in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers

Healthy | Diabetes

Japan
Emory University
Merck Sharp & Dohme LLC

Completed

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

Hyperglycemia | Type 2 Diabetes Mellitus | Hospitalization

United States

Search clinical trials for: Insulin Glargin (U100)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations